DOCARAVIMAB,MIROMAVIMAB
Background and Date of Approval
Docaravimab and miromavimab combination is approved for medical use in the treatment of rabies.
Uses
Docaravimab + miromavimab is prescribed for post-exposure risk prevention after contact with an infected animal or an animal suspected to have a rabies infection.
How is it administered?
Docaravimab + miromavimab is available as an injection in two different strengths: 600IU and 1500IU. It is primarily administered intramuscularly, typically at the site of the potential rabies exposure.
Side Effects
Common side effects of Docaravimab + miromavimab may include localized reactions at the injection site, such as pain, swelling, redness, and a low-grade fever. Serious side effects are rare but may involve severe allergic reactions (anaphylaxis) that can result in symptoms like difficulty breathing, facial or throat swelling, hives, and a drop in blood pressure.
Warnings
Docaravimab + miromavimab may risk severe allergic reactions, including anaphylaxis, which can be life-threatening. Some individuals may experience a mild increase in body temperature (low-grade fever) as a common side effect.
Precautions
Before initiating the treatment, consult your healthcare professional and disclose any known allergies to similar products. During and after the treatment, keenly monitor for any adverse reactions. This injection is safe to use in children. Talk to your physician if you are pregnant or breastfeeding before taking docaravimab + miromavimab injection.
Word of Advice
Patients prescribed docaravimab + miromavimab injection should prioritise safety through clear communication with their healthcare provider. Strict adherence to the prescribed dosage and schedule is essential. When this injection is combined with rabies vaccine, compliance with the recommended vaccination schedule must be maintained. All scheduled follow-up appointments should be attended for appropriate monitoring. Patients should familiarise themselves with signs of severe reactions and seek immediate medical attention if these occur. Any changes in health status should be communicated promptly to the healthcare provider. Patients who are pregnant or planning to breastfeed should discuss these plans with their healthcare provider. Personalised advice from healthcare professionals should always be sought to ensure safety during treatment.
References
Zydus; the U.S. Food And Drug Administration (FDA) [Accessed on 14/08/202] https://www.fda.gov/media/106517/download Kevinkumar Kansagra et al. A Phase 3, Randomised, Open-Label, Non-inferiority Trial Evaluating Anti-Rabies Monoclonal Antibody Cocktail (TwinrabTM) Against Human Rabies Immunoglobulin (HRIG); Clinical Infectious Diseases; Published on 17/06/2020; Accessed on 14/08/2021; https://pubmed.ncbi.nlm.nih.gov/32556113/ De Melo GD et al., A combination of two human monoclonal antibodies cures symptomatic rabies; EMBO Mol Med; Published on 06/11/2020; Accessed on 13/11/2023 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645379/ Anti-rabies virus monoclonal antibodies, World Health Organisation (WHO), https://list.essentialmeds.org/recommendations/1220/print?format=pdf
Frequently Asked Questions
What is docaravimab and miromavimab used for?
Docaravimab + miromavimab is used in the treatment of Rabies.
How long does the immunity provided by docaravimab and miromavimab last?
The immunity provided by docaravimab and miromavimab is not lifelong. It offers protection for a limited period. Your healthcare provider will guide you on the need for booster doses or additional vaccinations to maintain immunity.
Is it safe to drive while undergoing treatment with docaravimab + miromavimab injection?
The impact of docaravimab + miromavimab on driving ability is unknown. It's advisable to consult your doctor for personalized advice. Until you know how the medication affects you, it's wise to exercise caution while driving or operating heavy machinery.
What should I do if I miss a scheduled injection of docaravimab + miromavimab?
It's important to adhere to the prescribed dosage and schedule. If you miss a scheduled injection, contact your healthcare provider immediately for guidance. They will provide instructions on whether a makeup dose is needed and the appropriate course of action.
Are there specific signs of severe reactions that I should watch for during the treatment with docaravimab + miromavimab?
Yes, it is essential to be aware of signs of severe reactions, especially allergies. These may include difficulty breathing, swelling, or severe injection site pain. If you experience any of these symptoms or other concerning issues, seek immediate medical attention and inform your healthcare provider promptly.